Topical ocular delivery of NSAIDs

AAPS Journal

Volumn 10, Issue 2, 2008, Pages 229-241

  Ahuja, Munish ^a   Dhake, Avinash S ^b   Sharma, Surendra K ^a   Majumdar, Dipak K ^c  

^a GURU JAMBHESHWAR UNIVERSITY OF SCIENCE AND TECHNOLOGY   (India)

^b LB Rao Institute of Pharmaceutical Education and Research   (India)

^c UNIVERSITY OF DELHI   (India)

Author keywords

Anti inflammatory; Cyclodextrins; Formulation; NSAID; Ocular; PGE2

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ARACHIDONIC ACID; BENDAZAC; BENZALKONIUM CHLORIDE; BROMFENAC; CORTICOSTEROID; CYCLODEXTRIN DERIVATIVE; DICLOFENAC; INDOMETACIN; KETOPROFEN; KETOROLAC; LIPOSOME; LYSINE; NANOCAPSULE; NANOPARTICLE; NAPROXEN; NEPAFENAC; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; POLYMER; POLYSORBATE 80; POTASSIUM; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; SOLUBILIZER; SUPROFEN; TROMETAMOL; UNINDEXED DRUG;

AQUEOUS SOLUTION; BURNING SENSATION; CATARACT; CORNEA; CORNEA PERMEABILITY; DIGESTIVE SYSTEM ULCER; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG INCOMPATIBILITY; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; DRUG USE; EYE DISCOMFORT; EYE INFLAMMATION; EYE IRRITATION; EYE PAIN; EYE TOXICITY; HUMAN; INTRAOCULAR HYPERTENSION; IONTOPHORESIS; NONHUMAN; OCULAR PRURITUS; OINTMENT; PHOTOPHOBIA; PKA; PRECIPITATION; REVIEW; STRUCTURE ACTIVITY RELATION; SUSPENSION; TISSUE LEVEL; UVEITIS;

ADMINISTRATION, TOPICAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLODEXTRINS; DRUG CARRIERS; EYE; EYE DISEASES; HUMANS; MOLECULAR STRUCTURE; NANOPARTICLES; OPHTHALMIC SOLUTIONS;

EID: 53849143939     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-008-9024-9     Document Type: Review

References (103)

1. J. Harry, and G. Mission. Clinical Ophthalmic Pathology, Principles of Diseases of the Eye and Associated Structures, Butterworth Heinemann, Oxford, UK, 2001.
2. J. H. Chang, and H. Chung. Non-steroidal anti-inflammatory drug and endotoxin induced uveitis. Korean. J. Ophthalmol. 7:35-42 (1993).
3. J. Polansky, and R. Weinreb. Steroids as anti-inflammatory agent. In M. Sears (ed.), Pharmacology of the Eye, Springer, New York, 1984, pp. 460-583.
4. M. Raizman. Corticosteroid therapy of eye diseases; fifty years later. Arch. Ophthalmol. 114:1000-1001 (1996).
5. L. Waterbury, E. A. Kunysz, and R. Bewerman. Effect of steroidal and non steroidal anti-inflammatory agents on corneal wound healing. J. Ocul. Pharmacol. 3:43-54 (1987).
6. R. Schalnus. Topical nonsteroidal anti-inflammatory therapy in ophthalmology. Ophthalmologica 217:89-98 (2003).
7. B. M. Bandare, P. R. Sankaridurg, and M. D. Willcox. Non-steroidal anti-inflammatory agents decrease bacterial colonization of contact lenses and prevent adhesion to human corneal epithelial cells. Curr. Eye Res. 29:245-251 (2004).
8. Y. Rojanasakul, and J. R. Robinson. Transport mechanisms of the cornea: characterization of barrier permselectivity. Int. J. Pharm. 55:237-246 (1989).
9. M. Gupta, and D. K. Majumdar. Effect of concentration, pH and preservatives on in vitro transcorneal permeation of ibuprofen and flurbiprofen from non-buffered aqueous drops. Indian J. Exp. Biol. 35:844-849 (1997).
10. M. Ahuja, A. S. Dhake, and D. K. Majumdar. Effect of formulation factors on in vitro permeation of diclofenac from experimental and marketed aqueous eye drops through excised goat cornea. Yakugaku Zasshi 126:1369-1375 (2006).
11. M. B. Abelson, S. I. Butrus, G. H. Kliman, D. L. Larson, E. J. Corey, and L. M. Smith. Topical arachidonic acid: A model for screening anti-inflammatory agents. J. Ocul. Pharmacol. 3:63-75 (1987).
12. A. Regnier, M. Bonnefoi, and F. Lescure. Effect of lysine-acetylsalicylate and phenylbutazone premedication on the protein content of secondary aqueous humor in the dog. Res. Vet. Sci. 37:26-29 (1984).
13. S. R. Guimaraes-Filho, C. J. Simal, and H. G. Almeida. Comparison of the anti-inflammatory effects of topically applied aspirin and indomethacin following photocoagulation of the rabbit iris. Braz. J. Med. Biol. Res. 25:67-73 (1992).
14. G. Ciprandi, S. Buscaglia, M. Tosca, and G. W. Canonica. Topical acetylsalicylic acid in the treatment of allergic pollinosic conjunctivitis. J. Investig. Allergol. Clin. Immunol. 2:15-18 (1992).
15. R. Blakytny, and J. J. Harding. Prevention of cataract in diabetic rats by aspirin, paracetamol (acetaminophen) and ibuprofen. Exp. Eye Res. 54:509-518 (1992).
16. S. K. Gupta, S. Joshi, R. Tandon, and P. Mathur. Topical aspirin provides protection against galactosemic cataract. Indian J. Ophthalmol. 45:221-225 (1997).
17. M. Voigt, M. Kralinger G. Kieselbach, et al. Ocular aspirin distribution: A comparison of intravenous, topical, and coulomb-controlled iontophoresis administration. Invest. Ophthalmol. Vis. Sci. 43:3299-3306 (2002).
18. C. S. Sweetman. Martindale: The Complete Drug Reference, 34th edn. Pharmaceutical Press, London, 2005.
19. L. I. Kahanne, J. Bogi, A. Farkas, F. H. Tudos, and G. Imre. Indosol - a nonsteroidal anti-inflammatory drug with therapeutic efficacy. Acta Pharm. Hung. 64:125-129 (1994).
20. N. Vulovic, M. Primorac, M. Stupar, and J. L. Ford. Some studies into the properties of indomethacin suspensions intended for ophthalmic use. Int. J. Pharm. 55:123-128 (1989).
21. P. Chetoni, L. Panichi, S. Burgalassi, U. Bendli, and M. F. Seattone. Pharmacokinetics and anti-inflammatory activity in rabbits of a novel indomethacin ophthalmic solution. J. Ocul. Pharmacol. Ther. 16:363-372 (2000).
22. E. Dimitrova, S. Bogdannova, M. Mitcheva, I. Tanev, and V. E. Minko. Development of model aqueous ophthalmic solution of indomethacin. Drug Dev. Ind. Pharm. 26:1297-1301 (2000).
23. D. R. Sanders, B. Goldstick, C. Kraff, R. Hutchins, M. S. Bernstein, and M. A. Evans. Aqueous penetration of oral and topical indomethacin in humans. Arch. Ophthalmol. 101:1614 (1983).
24. S. Muchtar, M. Abdulrazik, J. Frucht-Pery, and S. Benita. Ex vivo permeation study of indomethacin from a submicron emulsion through albino rabbit cornea. J. Control. Release 44:55 (1997).
25. P. Calvo, J. L. Vila-Jato, and M. J. Alonso. Comparative in vitro evaluation of several colloidal systems, nanoparticles, nanocapsules and nanoemulsions as ocular drug carriers. J. Pharm. Sci. 85:530-536 (1996).
26. P. Calvo, M. J. Alonso, J. L. Vila-Jato, and J. R. Robinson. Improved ocular bioavailability of indomethacin by novel ocular drug carriers. J. Pharm. Pharmacol. 48:1147-1152 (1996).
27. J. Balasubramaniam, S. Kant, and J. K. Pandit. In vitro and in vivo evaluation of the gelrite gellan gum-based ocular delivery system for indomethacin. Acta Pharm. 53:251-261 (2003).
28. J. K. Pandit, S. L. Harikumar, D. N. Mishra, and J. Balasubramaniam. Effect of physical cross-linking on in vitro and ex vivo permeation of indomethacin from polyvinyl alcohol ocular inserts. Indian J. Pharm. Sci. 65:146-151 (2003).
29. M. T. Kumar, C. Rajeshwari, J. Balasubramaniam, and J. K. Pandit. In vitro and in vivo characterization of scleral implants of indomethacin. Drug Deliv. 10:269-275 (2003).
30. J. Balasubramaniam, M. T. Kumar, J. K. Pandit, and S. Kant. Gellan-based scleral implants of indomethacin: In vitro and in vivo evaluation. Drug Deliv. 11:371-379 (2004).
31. J. A. Balfour, and S. P. Clissold. Bendazac lysine. A review of its pharmacological properties and therapeutic potential in the management of cataracts. Drugs 39:575-596 (1990).
32. W. Lund. The Pharmaceutical Codex: Principles and Practice of Pharmaceutics, Pharmaceutical Press, London, 1994.
33. O. Reer, T. K. Bock, and B. W. Muller. In vitro corneal permeability of diclofenac sodium in formulations containing cyclodextrins compared to the commercial product Voltaren ophtha. J. Pharm. Sci. 83:1345-1349 (1994).
34. L. Baydoun, and C. C. Muller-Goymann. Influence of n-octenylsuccinate starch on in vitro permeation of sodium diclofenac across excised porcine cornea in comparison to voltaren ophtha. Eur. J. Pharm. Biopharm. 56:73-79 (2003).
35. S. Desai, R. Bawa, inventors. Alcon Laboratories Inc., assignee. Topical ophthalmic acidic drug formulations. US Patent 5 558 876. September 24, 1996.
36. A. C. Guidera, J. I. Luchs, and I. J. Udell. Keratitis, ulceration and perforation associated with topical non-steroidal anti-inflammatory drugs. Ophthalmology 108:936-944 (2001).
37. S. L. Hargrave, J. C. Jang M. E. Fini. Possible role of the vit E solubilizer in topical diclofenac on matrix metallo proteinase expression in corneal melting. Ophthalmology 109:343-350 (2002).
38. M. Ahuja, S. K. Sharma, and D. K. Majumdar. In vitro corneal permeation of diclofenac from oil drops. Yakugaku Zasshi 127:1739-1745 (2007).
39. J. D. Quintana-Hau, E. Cruz-Olmos, M. I. Lopez-Sanchez, et al. Characterization of the novel ophthalmic drug carrier Sophisen in two of its derivatives: 3A Ofteno and Modusik-A Ofteno. Drug Dev. Ind. Pharm. 31:263-269 (2005).
40. V. Sankar, K. Chandrasekaran, S. Durga, et al. Formulation and stability evaluation of diclofenac sodium ophthalmic gels. Indian J. Pharm. Sci. 6:473-476 (2005).
41. V. Sankar, A. K. Chandrasekaran, S. Durga, et al. Design and evaluation of diclofenac sodium ophthalmic inserts. Acta Pharm. Sciencia 48:5-10 (2006).
42. M. Hornof, W. Weyenberg, A. Ludwig, and A. Bernkop-Schnurcha. Mucoadhesive ocular insert based on thiolated poly acrylic acid): development and in vivo evaluation in humans. J. Control Rel. 89:419-428 (2003).
43. K. X. Sun, A. P. Wang, L. J. Huang, R. C. Liang, and K. Liu. Preparation of diclofenac sodium liposomes and its ocular pharmacokinetics. Yao Xue Xue Bao 41:1094-1098 (2006).
44. A. Guzman, F. Yuste, R. A. Toscano, J. M. Young, A. R. Van Horn, and J. M. Muchowski. Absolute configuration of (-)-5-benzoyl-1, 2-dihydro-3 H -pyrrolo [1, 2- a] pyrrole-1-carboxylic acid, the active enantiomer of ketorolac. J. Med. Chem. 29:589-591 (1986).
45. H. P. Sandoval, L. E. De Castro, D. T. Vroman, and K. D. Solomon. Evaluation of 0.4% ketorolac tromethamine ophthalmic solution versus 0.5% ketorolac tromethamine ophthalmic solution after phacoemulsification and intraocular lens implantation. J. Ocular Pharmacol. Ther. 22:251-257 (2006).
46. M. Malhotra, and D. K. Majumdar. In vitro transcorneal permeation of ketorolac tromethamine from buffered and non-buffered aqueous ocular drops. Indian J. Exp. Biol. 35:941-947 (1997).
47. L. Gu, H. S. Chiang, and A. Becker. Kinetics and mechanisms of the autoxidation of ketorolac tromethamine in aqueous solution. Int. J. Pharm. 41:95-104 (1988).
48. M. Malhotra, and D. K. Majumdar. Effect of preservative, antioxidant and viscolizing agents on in vitro transcorneal permeation of ketorolac tromethamine. Indian J. Exp. Biol. 4:555-559 (2002).
49. M. Malhotra, and D. K. Majumdar. In vitro transcorneal permeation of ketorolac from oil based ocular drops and ophthalmic ointment. Indian J. Exp. Biol. 35:1324-1330 (1997).
50. M. Malhotra, and D. K. Majumdar. In vivo ocular availability of ketorolac following ocular instillations of aqueous, oil and ointment formulations to normal corneas of rabbits: A technical note. AAPS PharmSci Tech 6(3):65 (2005).
51. H. E. Kennah, S. Higney, P. E. Laux, J. D. Dorko, and C. S. Barrow. An objective procedure for quantitating eye irritation based upon changes of corneal thickness. Fundam. Appl. Toxicol. 12:258-268 (1989).
52. M. Malhotra, and D. K. Majumdar. Aqueous, oil and ointment formulations of ketorolac: Efficacy against prostaglandin E2-induced ocular inflammation and safety: A technical note. AAPS PharmSci. Tech. 7(4):96 (2006).
53. P. S. Jayaprakash, C. C. James, N. S. M. G. Rajan, S. Saisivam, and M. Nagarajan. Design and evaluation of ketorolac tromethamine ocuserts. Indian J. Pharm. Sci. 62:334-338 (2000).
54. A. K. Gupta, S. Madan, D. K. Majumdar, and A. Maitra. Ketorolac entrapped in polymeric micelles: Preparation, characterization and ocular anti-inflammatory studies. Int. J. Pharm. 209:1-14 (2000).
55. Da. Gamache, G. Graff, M. T. Brady, J. M. Spellman, and J. M. Yanni. Nepafenac a unique non steroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of anti-inflammatory efficacy. Inflammation 24:357-369 (2000).
56. T. L. Ke, G. Graff, J. M. Spellman, and J. M. Yanni. Nepafenac a unique non steroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: II In vitro bioactivation and permeation of external ocular barriers. Inflammation 24:371-384 (2000).
57. M. A. Kapin, J. M. Yanni, M. T. Brady, et al. Inflammation-mediated retinal edema in the rabbit is inhibited by topical nepafenac. Inflammation 27:281-291 (2003).
58. F. A. Bucci, L. D. Waterbury, and L. M. Amico. Prostaglandin E2 inhibition and aqueous concentration of ketorolac 0.4% (Acular LS); and nepafenac 0.1% (Nevanac) in patients undergoing phacoemulsification. Am. J. Ophthalmol. 144:146-147 (2007).
59. S. S. Lane, S. S. Modi, R. P. Lehman, and E. J. Holland. Nepafenac ophthalmic suspension 0.1% for the prevention and treatment of ocular inflammation associated with cataract surgery. J. Cataract Refract. Surg. 33:53-58 (2007).
60. D. A. Walsh, H. W. Moran, D. A. Shamblee, et al. Antiinflammatory agents. 3. Synthesis and pharmacological evaluation of 2-amino-3-benzoylphenylacetic acid and analogues. J. Med. Chem. 27:1379-88 (1984).
61. The New Drug Application 020535. The US FDA, Centre for Drug Evaluation and Research Website. Available at: http://www.fda.gov/cder/foi/nda/97/ 020535apDuract_chemr_EA.pdf. Accessed October 9th, 2007.
62. E. D. Donnenfeld, E. J. Holland, R. H. Stewart, J. A. Gow, and L. R. Grillone. Bromfenac ophthalmic solution 0.09% (Xibrom) for postoperative ocular pain and inflammation. Ophthalmology 114:1653-1662 (2007).
63. J. M. Yanni, G. Graff, M. R. Hellberg, inventors. Alcon Laboratories Inc., assignee. Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders. US Patent 5 475 034. December 12, 1995.
64. L. D. Waterbury, D. Silliman, and T. Jolas. Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr. Med. Res. Opin. 22:1133-1140 (2006).
65. T. Ogawa, T. Sakaue, T. Terai, and C. Fukiage. Effects of bromfenac sodium, non steroidal anti-inflammatory drug on acute ocular inflammation. Nippon Gakka Gakkai Zasshi 99:406-411 (1995).
66. C. Bucolo, and A. Spadaro. Pharmacological evaluation of anti-inflammatory pyrrole-acetic acid derivative eye drops. J. Ocul. Pharmacol. Ther. 13:353-361 (1997).
67. W. Martin, G. Koselowske, H. Toberich, T. Kerkmann, B. Marigold, and J. Augustin. Pharmacokinetics and absolute bioavailability of ibuprofen after oral administration of ibuprofen lysine in man. Biopharm. Drug Dispos. 11:265-278 (1990).
68. S. R. Chakradhara, R. D. Schoenwald, C. F. Barfknecht, and S. L. Laban. Biopharmaceutical evaluation of ibufenac, ibuprofen and their hydroxyethoxy analogs in the rabbit eye. J. Pharmacokinet. Biopharm. 20:357-388 (1992).
69. L. Baydoun, A. Duvel, R. Daniels, et al. Comparison of different ibuprofen-amino acid compounds with respect to emulsifying and cytotoxic properties. Int. J. Pharm. 274:157-165 (2004).
70. R. Pignatello, C. Bucolo, P. Ferrara, A. Maltese, A. Puleo, and G. Puglisi. Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen. Eur. J. Pharm. Sci. 16:53-61 (2002).
71. A. A. Van Sorge, P. H. Wijnen, J. L. Van Delft, V. M. W. Bodelier, P. H. Wijnen, and N. J. Van Haeringen. Specificity of flurbiprofen and enantiomers for inhibition of prostaglandin synthesis in bovine iris/ ciliary body. Prostaglandins 55:169-177 (1998).
72. A. A. Van Sorge, P. H. Wijnen, J. L. Van Delft, V. M. W. Bodelier, P. H. Wijnen, and N. J. Van Haeringen. Flurbiprofen, S (+) eye drops: formulation, enantiomeric assay, shelf life and pharmacology. Pharm. World Sci. 21:91-95 (1999).
73. D. D. Tang-Liu, S. S. Liu, and R. J. Weinkam. Ocular and systemic bioavailability of ophthalmic flurbiprofen. J. Pharmacokinet. Biopharm. 12:611-626 (1984).
74. K. Masuda, T. Ikari, T. Matsuyama, A. Terashima, Goto Takao, inventors, Kakenyaku Kako Co. Ltd., Japan, assignee. Anti-inflammatory ophthalmic solution and process for preparing the same. US patent 4 474 811. October 2, 1984.
75. G. Graff, M. R. Hellberg, J. M. Yanni, inventors, Alcon laboratories Inc. assignee. Method of treating ocular inflammatory and angiogenesis-related disorders of the posterior segment of the eye using an amide derivative of flurbiprofen or ketorolac. US patent 6 646 003. November 11, 2003.
76. R. Pignatello, C. Bucolo, G. Spedalieri, A. Maltese, and G. Puglisi. Flurbiprofen-loaded acrylate polymer nanosuspensions for ophthalmic application. Biomaterials 23:3247-3255 (2002).
77. E. Vega, M. A. Egea, O. Valls, M. Espina, and M. L. Garcia. Flurbiprofen loaded biodegradable nanoparticles for ophthalmic administration. J. Pharm. Sci. 95:2393-2405 (2006).
78. P. S. Kulkarni, and B. D. Srinivasan. Anti-inflammatory effects of ketoprofen in rabbit corneal epithelial wound model. Exp. Eye Res. 41:267-73 (1985).
79. M. J. Nachajski, and M. M. Zgoda. Selected Rofams as a micellar solubilizers for diclofenac and naproxen in the environment of the standard vehicle for eye drops. Polim. Med. 35:39-47 (2005).
80. S. Spampinato, A. Marino, C. Bucolo, M. Canossa, T. Bachetti, and S. Mangiafico. Effects of sodium naproxen eye drops on rabbit ocular inflammation induced by sodium arachidonate. J. Ocul. Pharmacol. 7:125-133 (1991).
81. C. Bucolo, and A. Spadaro. Effect of sodium naproxen on inflammatory response induced by anterior chamber paracentesis in the rabbit. J. Pharm. Pharmacol. 47:708-712 (1995).
82. P. Russo, V. Papa, S. Russo, et al. Topical nonsteroidal anti-inflammatory drugs in uncomplicated cataract surgery: Effect of sodium naproxen. Eur. J. Ophthalmol. 15:598-606 (2005).
83. V. Papa, G. Milazzo, M. Santacono, et al. Naproxen ophthalmic solution to manage inflammation after phacoemulsification. J. Cataract Refract. Surg. 28:321-327 (2002).
84. C. Bucolo, and A. Maltese. Pharmacological profile of oxaprozin eye drops. J. Ocul. Pharmacol. Ther. 18:75-81 (2002).
85. Z. Liu, J. Li, S. Nie, H. Guo, and W. Pan. Effects of Transcutol P on the corneal permeability of drugs and evaluation of its ocular irritation of rabbit eyes. J. Pharm. Pharmacol. 58:45-50 (2006).
86. C. Torron, E. Ferrer, O. Ruiz-Moreno, et al. Effect of topical pranoprofen on the lipoxygenase metabolism of the arachidonic acid in endotoxin-induced uveitis. Arch. Soc. Esp. Oftalmol. 75:377-382 (2000).
87. I. Akyol-Salman, D. Lece-Sertoz, and O. Baykal. Topical pranoprofen 0.1% is as effective anti-inflammatory and analgesic agent as diclofenac sodium 0.1% after strabismus surgery. J. Ocul. Pharmacol. Ther. 23:280-283 (2007).
88. T. Ogawa, K. Ohara, and H. Shimizu. Effects of pretreatment with mydriatics on intraocular penetration of 0.1% pranoprofen. Jpn. J. Ophthalmol. 37:47-55 (1993).
89. K. Ogata, Y. Yamamoto, Y. Ozake, inventors, Yoshitomi Pharmaceutical Industries, Ltd.; Senju Pharmaceutical Co. Ltd., Japan, assignee. Ophthalmic pranoprofen compositions. US patent 4 607 038. August 19, 1986.
90. K. Doi, H. Sawa, Y. Ozaki, Y. Kinurra, inventors. Senju Pharmaceutical Co. Ltd.; Yoshitomi Pharmaceutical Industries Ltd., Japan, assignee. Method for stabilizing pranoprofen and stable liquid preparation of pranoprofen. US patent 5 856 345. January 5, 1999.
91. S. Miyagi, Y. Horibe, inventors. Santen Pharmaceutical Co. Ltd., Japan, assignee. Pranoprofen eye drops containing organic amine. US patent 6 281 224 B1. August 8, 2001.
92. T. S. Wood, R. H. Stewart, R. W. Bowman, J. P. McCulley, and T.A. Reaves Jr. Suprofen treatment of contact lens-associated giant papillary conjunctivitis. Ophthalmology 95:822-826 (1988).
93. B. P. Lee, A. Kupferman, and H. M. Leibowitz. Effect of suprofen on corneal wound healing. Arch. Ophthalmol. 103:95-97 (1985).
94. H. M. Leibowitz, W. J. Ryan, A. Kupferman, and L. DeSantis. Bioavailability and corneal anti-inflammatory effect of topical suprofen. Invest. Ophthalmol. Vis. Sci. 27:628-631 (1986).
95. D. A. Ward. Comparative efficacy of topically applied flurbiprofen, diclofenac, tolmetin, and suprofen for the treatment of experimentally induced blood-aqueous barrier disruption in dogs. Am. J. Vet. Res. 57:875-878 (1996).
96. S. H. Gerson, W. H. Wesley, inventors, Alcon Laboratories Inc., assignee.(+)-Suprofen esters and amides as ophthalmic anti-inflammatory agents. US patent 5 013 751.May 7, 1991.
97. I. Ahmed, inventor, Pfizer Inc., assignee. Ophthalmic piroxicam solution. US patent 5 362 758. November 8, 1994.
98. M. De Bernardi, A. Tafi, D. Mazzacane, G. Zennaro, E. Bozzo Costa, and S. Contos. Effects of topical treatment with piroxicam on prostaglandin synthesis in experimental uveitis. Int. J. Tissue React. 9:361-364 (1987).
99. M. T. Dorigo, D. Doro, and A. Cecchinato. Aqueous prostaglandin E2 and intraocular pressure after argon laser trabeculoplasty in glaucoma patients pretreated with topical piroxicam. Int. J. Tissue React. 9:73-75 (1987).
100. D. Costin, S. Popa, and C. Costea. Clinical study on the tolerance and efficacy of piroxicam used in cataract surgery, compared with diclofenac and indomethacin. Rev. Med. Chir. Soc. Med. Nat. Iasi 109:305-313 (2005).
101. K. Adibkia, S. M. R. Siahi, A. Nokhodchi, et al. Piroxicam nanoparticles for ocular delivery: Physicochemical characterization and implementation in endotoxin-induced uveitis. J. Drug Target 15:407-416 (2007).
102. A. C. Moffat, M. D. Osselton, B. Widdop, and L. Y. Galichet. Clarke's Analysis of Drugs and Poisons, 3rd edn. Pharmaceutical Press, London, 2004.
103. The New Drug Application 020776. The US FDA, Centre for Drug Evaluation and Research Website. Available at: http://www.fda.gov/cder/foi/label/ 2002/18841s12s16lbl.pdf. Accessed December 8th, 2007.